Direct  ||| S:0 E:7 ||| NNP
Flow  ||| S:7 E:12 ||| NNP
Medical  ||| S:12 E:20 ||| NNP
valve  ||| S:20 E:26 ||| VBD
To  ||| S:26 E:29 ||| TO
study  ||| S:29 E:35 ||| VB
the  ||| S:35 E:39 ||| DT
feasibility  ||| S:39 E:51 ||| NN
and  ||| S:51 E:55 ||| CC
safety  ||| S:55 E:62 ||| NN
of  ||| S:62 E:65 ||| IN
the  ||| S:65 E:69 ||| DT
non-metallic ||| S:69 E:81 ||| JJ
,  ||| S:81 E:83 ||| ,
repositionable  ||| S:83 E:98 ||| NN
and  ||| S:98 E:102 ||| CC
retrievable  ||| S:102 E:114 ||| JJ
percutaneous  ||| S:114 E:127 ||| JJ
Direct  ||| S:127 E:134 ||| NNP
Flow  ||| S:134 E:139 ||| NNP
Medical  ||| S:139 E:147 ||| NNP
( ||| S:147 E:148 ||| -LRB-
DFM ||| S:148 E:151 ||| NNP
)  ||| S:151 E:153 ||| -RRB-
aortic  ||| S:153 E:160 ||| JJ
valve ||| S:160 E:165 ||| NN
.  ||| S:165 E:167 ||| .
The  ||| S:167 E:171 ||| DT
first-generation  ||| S:171 E:188 ||| JJ
( ||| S:188 E:189 ||| -LRB-
22  ||| S:189 E:192 ||| CD
Fr ||| S:192 E:194 ||| NNP
)  ||| S:194 E:196 ||| -RRB-
DFM  ||| S:196 E:200 ||| NNP
valve  ||| S:200 E:206 ||| NN
has  ||| S:206 E:210 ||| VBZ
been  ||| S:210 E:215 ||| VBN
evaluated  ||| S:215 E:225 ||| VBN
in  ||| S:225 E:228 ||| IN
a  ||| S:228 E:230 ||| DT
prospective  ||| S:230 E:242 ||| JJ
non-randomised  ||| S:242 E:257 ||| JJ
trial  ||| S:257 E:263 ||| NN
in  ||| S:263 E:266 ||| IN
31  ||| S:266 E:269 ||| CD
high-risk  ||| S:269 E:279 ||| JJ
patients  ||| S:279 E:288 ||| NNS
with  ||| S:288 E:293 ||| IN
severe  ||| S:293 E:300 ||| JJ
symptomatic  ||| S:300 E:312 ||| JJ
aortic  ||| S:312 E:319 ||| JJ
stenosis ||| S:319 E:327 ||| NN
.  ||| S:327 E:329 ||| .
The  ||| S:329 E:333 ||| DT
procedural  ||| S:333 E:344 ||| JJ
success  ||| S:344 E:352 ||| NN
rate  ||| S:352 E:357 ||| NN
was  ||| S:357 E:361 ||| VBD
71 ||| S:361 E:363 ||| CD
% ||| S:363 E:364 ||| NN
,  ||| S:364 E:366 ||| ,
30-day  ||| S:366 E:373 ||| JJ
mortality  ||| S:373 E:383 ||| NN
12.9 ||| S:383 E:387 ||| CD
% ||| S:387 E:388 ||| NN
.  ||| S:388 E:390 ||| .
Survival  ||| S:390 E:399 ||| NN
at  ||| S:399 E:402 ||| IN
three  ||| S:402 E:408 ||| CD
years  ||| S:408 E:414 ||| NNS
was  ||| S:414 E:418 ||| VBD
60 ||| S:418 E:420 ||| CD
%  ||| S:420 E:422 ||| NN
and  ||| S:422 E:426 ||| CC
all  ||| S:426 E:430 ||| DT
patients  ||| S:430 E:439 ||| NNS
had  ||| S:439 E:443 ||| VBD
none ||| S:443 E:447 ||| NN
/ ||| S:447 E:448 ||| FW
trace  ||| S:448 E:454 ||| FW
aortic  ||| S:454 E:461 ||| FW
regurgitation  ||| S:461 E:475 ||| FW
at  ||| S:475 E:478 ||| IN
three  ||| S:478 E:484 ||| CD
years ||| S:484 E:489 ||| NNS
.  ||| S:489 E:491 ||| .
Based  ||| S:491 E:497 ||| VBN
on  ||| S:497 E:500 ||| IN
the  ||| S:500 E:504 ||| DT
initial  ||| S:504 E:512 ||| JJ
experience ||| S:512 E:522 ||| NN
,  ||| S:522 E:524 ||| ,
an  ||| S:524 E:527 ||| DT
18  ||| S:527 E:530 ||| CD
Fr  ||| S:530 E:533 ||| JJ
device  ||| S:533 E:540 ||| NN
has  ||| S:540 E:544 ||| VBZ
been  ||| S:544 E:549 ||| VBN
developed  ||| S:549 E:559 ||| VBN
with  ||| S:559 E:564 ||| IN
several  ||| S:564 E:572 ||| JJ
important  ||| S:572 E:582 ||| JJ
revisions  ||| S:582 E:592 ||| NNS
to  ||| S:592 E:595 ||| TO
improve  ||| S:595 E:603 ||| VB
the  ||| S:603 E:607 ||| DT
efficacy  ||| S:607 E:616 ||| NN
and  ||| S:616 E:620 ||| CC
safety  ||| S:620 E:627 ||| NN
of  ||| S:627 E:630 ||| IN
the  ||| S:630 E:634 ||| DT
procedure ||| S:634 E:643 ||| NN
.  ||| S:643 E:645 ||| .
Currently ||| S:645 E:654 ||| RB
,  ||| S:654 E:656 ||| ,
it  ||| S:656 E:659 ||| PRP
is  ||| S:659 E:662 ||| VBZ
being  ||| S:662 E:668 ||| VBG
evaluated  ||| S:668 E:678 ||| VBN
in  ||| S:678 E:681 ||| IN
a  ||| S:681 E:683 ||| DT
multicentre  ||| S:683 E:695 ||| JJ
non-randomised  ||| S:695 E:710 ||| JJ
trial  ||| S:710 E:716 ||| NN
which  ||| S:716 E:722 ||| WDT
will  ||| S:722 E:727 ||| MD
include  ||| S:727 E:735 ||| VB
100  ||| S:735 E:739 ||| CD
patients ||| S:739 E:747 ||| NNS
.  ||| S:747 E:749 ||| .
The  ||| S:749 E:753 ||| DT
primary  ||| S:753 E:761 ||| JJ
endpoint  ||| S:761 E:770 ||| NN
is  ||| S:770 E:773 ||| VBZ
freedom  ||| S:773 E:781 ||| NN
from  ||| S:781 E:786 ||| IN
all-cause  ||| S:786 E:796 ||| JJ
mortality  ||| S:796 E:806 ||| NN
at  ||| S:806 E:809 ||| IN
30  ||| S:809 E:812 ||| CD
days ||| S:812 E:816 ||| NNS
.  ||| S:816 E:818 ||| .
The  ||| S:818 E:822 ||| DT
22  ||| S:822 E:825 ||| CD
Fr  ||| S:825 E:828 ||| NNP
DFM  ||| S:828 E:832 ||| NNP
valve  ||| S:832 E:838 ||| NN
has  ||| S:838 E:842 ||| VBZ
been  ||| S:842 E:847 ||| VBN
successfully  ||| S:847 E:860 ||| RB
assessed  ||| S:860 E:869 ||| VBN
in  ||| S:869 E:872 ||| IN
a  ||| S:872 E:874 ||| DT
first-in-man  ||| S:874 E:887 ||| JJ
feasibility  ||| S:887 E:899 ||| NN
and  ||| S:899 E:903 ||| CC
safety  ||| S:903 E:910 ||| NN
trial ||| S:910 E:915 ||| NN
.  ||| S:915 E:917 ||| .
Up  ||| S:917 E:920 ||| RB
to  ||| S:920 E:923 ||| TO
three-year  ||| S:923 E:934 ||| JJ
follow-up  ||| S:934 E:944 ||| NN
sustained  ||| S:944 E:954 ||| VBD
clinical  ||| S:954 E:963 ||| JJ
benefit  ||| S:963 E:971 ||| NN
and  ||| S:971 E:975 ||| CC
haemodynamic  ||| S:975 E:988 ||| JJ
performance  ||| S:988 E:1000 ||| NN
was  ||| S:1000 E:1004 ||| VBD
demonstrated  ||| S:1004 E:1017 ||| VBN
with  ||| S:1017 E:1022 ||| IN
no  ||| S:1022 E:1025 ||| DT
or  ||| S:1025 E:1028 ||| CC
trace  ||| S:1028 E:1034 ||| JJ
aortic  ||| S:1034 E:1041 ||| JJ
regurgitation  ||| S:1041 E:1055 ||| NN
in  ||| S:1055 E:1058 ||| IN
all  ||| S:1058 E:1062 ||| DT
patients ||| S:1062 E:1070 ||| NNS
.  ||| S:1070 E:1072 ||| .
The  ||| S:1072 E:1076 ||| DT
18  ||| S:1076 E:1079 ||| CD
Fr  ||| S:1079 E:1082 ||| NNP
DFM  ||| S:1082 E:1086 ||| NNP
valve  ||| S:1086 E:1092 ||| NN
is  ||| S:1092 E:1095 ||| VBZ
under  ||| S:1095 E:1101 ||| IN
investigation  ||| S:1101 E:1115 ||| NN
in  ||| S:1115 E:1118 ||| IN
an  ||| S:1118 E:1121 ||| DT
on-going  ||| S:1121 E:1130 ||| JJ
trial ||| S:1130 E:1135 ||| NN
.  ||| S:1135 E:1137 ||| .
